BCRX vs NTLA
BCRX: BioCryst Pharmaceuticals is a biotech company focused on commercializing and developing innovative therapies for hereditary angioedema and other rare diseases using structure-guided drug design. NTLA: CRISPR-based genome editing company developing in vivo therapies for rare genetic diseases including hereditary angioedema and ATTR amyloidosis.
Side-by-side fundamentals
| Metric | BCRX | NTLA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $9.51 | $11.13 | |
| Market cap as of 2026-07-23 | $2.4B | $1.6B | |
| P/E as of 2026-07-23 | 9.20 | n/a | |
| PEG as of 2026-07-23 | -0.01 | n/a | |
| Net margin as of 2026-07-23 | -51.7% | -597.0% | BCRX higher |
| Gross margin as of 2026-07-23 | +97.8% | n/a | |
| Operating margin as of 2026-07-23 | -45.1% | -636.6% | BCRX higher |
| ROE as of 2026-07-23 | -328.8% | -57.3% | NTLA higher |
| ROA as of 2026-07-23 | -97.3% | -46.1% | NTLA higher |
| Debt / equity as of 2026-07-23 | 2.26 | 0.00 | NTLA lower |
| Revenue growth (YoY) as of 2026-07-23 | +75.9% | +45.0% | BCRX higher |
| Revenue CAGR (3y) SEC XBRL | +22.8% | +9.1% | BCRX higher |
| Beta as of 2026-07-23 | 0.57 | 1.78 | |
| 1-year return as of 2026-07-22 close | +9.9% | -17.5% | BCRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.